A qualitative study to investigate community pharmacists' perceptions about identifying and addressing inappropriately prescribed analgesia.

OBJECTIVES: Inappropriate prescribing, particularly for analgesia, is a recognised global problem. This leads to increased morbidity and mortality and presents a significant challenge for patients and the healthcare system. There is a need to identify strategies that best identify inappropriately prescribed analgesia (IPA). This study aims to explore the perspectives and experiences of community pharmacists (CPs) about addressing IPA. METHODS: Semi-structured interviews informed by the Behaviour Change Wheel model and the Theoretical Domains Framework (TDF) were conducted with consenting community pharmacists. Transcripts were coded using a capability, opportunity, motivation model of behaviour (COM-B) model. The COM-B components were mapped to the TDF and behaviour change techniques (BCTs) were identified to address these. KEY FINDINGS: A total of 12 pharmacists who work in community pharmacies in England were interviewed between March and May 2021. COM-B components were identified through analysis and mapped to nine TDF domains. Component 1 referred to 'Capability' of CPs to be involved in addressing IPA (knowledge). Component 2 pertained to 'Opportunity' to identify IPA (e.g. social influence). The 'Motivation' component linked to five TDF domains (e.g. goals). Seventeen BCTs were identified to support CPs in addressing IPA (e.g. environmental context and resources domain mapped to 2 BCTs 'restructuring the physical and social environment'). CONCLUSIONS: CPs expressed mixed perceptions about their involvement in the deprescribing of IPA as part of their daily practice, but they stated that social and environmental barriers needed to be addressed to facilitate their involvement. The identified BCTs provide evidence-based strategies to help the involvement of CPs to identify IPA.

The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials.

BACKGROUND: There are increasing concerns regarding the abusive potential of gabapentinoids putting at risk patients with neuropathic pain requiring long-term pain management. The evidence to support this is rather inconcusive. AIM: This systematic review aimed to evaluate the safety and efficacy of gabapentinoids in the management of neuropathic pain with a focus on randomised controlled trials (RCTs) and categorising the side effects according to the body systems they were affecting. METHOD: Searches were conducted in MEDLINE (PubMed), EMBASE, Web of Science, PsycoINFO, and CINAHL (EBSCO), and included RCTs to identify and critically appraise studies investigating safety and therapeutic effects of gabapentionoids in adults with neuropathic pain. Data extraction was conducted using an established Cochrane form and the risk-of-bias tool was used in the assessment of quality. RESULTS: 50 studies (12,398 participants) were included. The majority of adverse events pertained to the nervous system (7 effects) or psychiatric (3 effects) disorders. There were more adverse effects reported with pregabalin (36 effects) than with gabapentin (22 effects). Six pregabalin studies reported euphoria as a side effect, while no studies reported euphoria with gabapentin. This was the only side effect that may correlate with addictive potential. Gabapentioids were reported to significantly reduce pain compared to placebo. CONCLUSION: Despite RCTs documenting the adverse events of gabapentionoids on the nervous system, there was no evidence of gabapentinoid use leading to addiction, suggesting an urgent need to design studies investigating their abusive potential.

A review and narrative synthesis of community pharmacist-led interventions to tackle medicines for pain that are misused.

OBJECTIVES: To undertake a state-of-the-art review and narrative synthesis of current evidence investigating community pharmacist-led interventions addressing analgesic medication misuse. To achieve the objective, a systematic database search was undertaken during October and November 2020 across Embase, Medline, Web of Science and Scopus. Community pharmacy interventions were mapped to the Behaviour Change Wheel to investigate the pharmacist and patient behaviours addressed by the interventions. Outcomes about process and effects were extracted. A risk of bias assessment was undertaken. KEY FINDINGS: Five studies undertaken in the USA and Northern Ireland were included. Brief Motivational Interviewing and Medication Therapy Management and the Opioid and Naloxone Education programme demonstrated positive process outcomes and feasibility in delivery. Intervention functions addressing patient and pharmacist behaviours across the studies included education, training, environmental restructuring and enablement. Restrictions were an additional intervention function targeting patient behaviour incorporated in one study. Pharmacist roles involved the identification of potential misusers/abusers, patient education, long-term management, prevention and referral. Low study numbers, non-experimental designs, high risk of bias, incomplete reporting of interventions and heterogeneous outcome measures limited evidence synthesis. SUMMARY: There is limited evidence of pharmacy interventions and their well-tested impact on pharmacists and patients. There is clinical and methodological heterogeneity across studies. It is pragmatic to suggest that a systems-thinking approach is adopted to investigate the potential role of community pharmacists and engage all stakeholders in the design of a theory-informed intervention. More high-quality studies including larger population sizes undertaken for longer periods of time that are rigorously reported are needed to improve the evidence base.